|Bid||96.18 x 1400|
|Ask||96.25 x 800|
|Day's Range||95.83 - 97.64|
|52 Week Range||72.97 - 98.79|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||1.03%|
|Beta (5Y Monthly)||1.57|
|Expense Ratio (net)||0.35%|
Biotech stocks had a fairly decent run in 2019, thanks to record deal flow , several path-breaking innovation in drug research & development and the positive broader market sentiment. New molecular entity ...
Biotech funds saw their steepest outflows since late July on the week of the biggest annual meeting for health-care investors.
The 38th annual JPMorgan Healthcare Conference, which is tipped off as the biggest health care investment symposium, kicks off Monday in San Francisco, California. From the high and mighty to the smallest ...
Broadly speaking, drug stocks have been some of the strongest performing names in the latter part of 2019.Since October 2019, the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) has rallied from a low of $96 to nearly $124. The SPDR S&P Biotech ETF (NYSE:XBI) exploded from $75 to a high of $98.79. Even ProShares Ultra NASDAQ Biotechnology (NASDAQ:BIB) popped from a low of $41 to a high of nearly $65.All despite concerns over potential changes to drug pricing policies with elections ahead.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"While we get the sense that biotech investors are cautious into 2020 with the election and broader macro concerns, we believe that macro issues are unlikely to have material fundamental impact," says Credit Suisse's Evan Seigerman.Wedbush analysts argue, "The fundamentals of the sector look strong. Biotech surged in the third quarter, approvals from the Food & Drug Administration are coming through above the average annual rate, the valuation of large-cap biotechs are attractive, and there have been significant mergers and acquisitions in past years."Plus, one of the biggest catalysts for future growth are the millions of retiring baby boomers.We're also seeing new, innovative treatments for a myriad of issues. In addition, such stocks are recession-proof because folks will always require medical attention. * 10 2019 Winners That Will Be 2020 Losers Here are three of the top biotech stocks to watch in the New Year. Top Drug Stocks: Fate Therapeutics (FATE)After struggling out the gate, Fate Therapeutics (NASDAQ:FATE) exploded from a low of $14 to $20 a share after posting positive trial results from its natural kill (NK) cell product candidate.With regards to data from its natural killer (NK) cell product candidate, "Current patient- and donor-specific CAR T-cell immunotherapies recognize only one antigen and fail to address the significant risk of relapse due to antigen escape. FT596 is ground-breaking in that it is designed to be available off-the-shelf for timely patient access and to promote deeper and more durable responses by targeting multiple tumor-associated antigens," said Bob Valamehr, Ph.D., Chief Development Officer of Fate Therapeutics.The company's other natural cell killer was also found to kill off cancer in a patient with acute myeloid leukemia (AML). Wells Fargo recently upgraded the FATE stock to an overweight rating with a target of $24. Axsome Therapeutics (AXSM)Axsome Therapeutics (NASDAQ:AXSM) had an explosive year. Since January 2019, AXSM stock exploded from a low of $2.64 to a recent high of $105.55. All after a series of major announcements, throughout the year. In January, for example, AXSM noted that its lead drug candidate, AXS-05 met its primary endpoint in a Phase II trial for major depressive disorder.Two months later, AXSM won FDA Breakthrough Therapy for the drug. By April, the drug also achieved its primary endpoint for smoking cessation. By December, its AXS-12 drug met its primary endpoint in a Phase II trial targeting narcolepsy.Then just two weeks ago, the AXSM stock ramped higher on news of positive late-state results for AXS-05, as a treatment of major depressive disorder. * 10 Stocks That Every 30-Year-Old Should Buy and Hold Forever "Given the documented medical need for more potent MDD therapies, and the fact that a whopping 17 million American adults suffer from this condition every year, according to the National Institutes of Health, this experimental depression med has a clear path toward blockbuster status," noted Motley Fool contributor George Budwell. Pfizer (PFE)Last year wasn't kind to Pfizer (NYSE:PFE) or its shareholders. In late July, PFE plunged 21% on company plans to combine its blockbuster drug-selling unit with Mylan (NYSE:MYL), and announced it was cutting its sales and adjusted earnings forecast.However, with a strong drug portfolio, acquisitions, and an undervalued stock, PFE is attracting interest once again. The company also just raised its dividend by 5.6%, which brings the new quarterly dividend to 38 cents from 36 cents payable March 6, 2020 to shareholders as of Jan. 31.Plus, "the valuation on new Pfizer looks appealing, given management's expectation of 6% annualized sales growth through 2025, which could produce 10%-plus yearly gains in earnings per share. New Pfizer has important patent-protected drugs like Ibrance for breast cancer and the pneumonia vaccine Prevnar, plus a strong pipeline," notes Barron's contributor Andrew Bary.As of this writing, Ian Cooper did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 2019 Winners That Will Be 2020 Losers * 5-Year Returns for 5 Dow Jones Stocks Entering 2020 * 5 Semiconductor Stocks to Buy for Big Gains In 2020 The post 3 Top Drug Stocks to Own In 2020 appeared first on InvestorPlace.
Amid a plethora of challenges, Wall Street was on a spectacular run over the last decade, rising from the depths of the financial crisis and Great Recession.
As Wall Street bulls rage on, investors can play high-beta ETFs to make the most of the Santa rally. These ETFs offer solid value and allay overpricing concerns.
Shares of Stealth BioTherapeutics tumbled 63% after it said a late-stage trial for its investigational treatment of primary mitochondrial myopathy, a muscular disease caused by genetic mutations, failed to meet the study's primary endpoint. Stealth said in a news release that it is reviewing its "operational resources" and plans to provide investors with additional guidance in January. Shares of the Newton, Mass.-based biotechnology company, which went public in February, are down 22% over the last three months. The SPDR S&P Biotech exchange-traded fund has gained 16% during the same three months.
The Food and Drug Administration on Wednesday issued a notice of proposed rulemaking that would allow the importation of some prescription drugs from Canada. States and "certain other non-federal government entities" would be able to submit importation proposals to the regulator, while drugmakers would also be able to obtain a national drug code for certain medications. Importing prescription drugs into the U.S. is an idea that has been increasingly offered up as a solution to drug shortages or a way to find cheaper medications. Colorado, Florida, and Vermont have all recently passed drug-importation laws. The drug industry opposes importation, generally. PhRMA, the pharmaceutical industry's lobbying group, criticized the proposal, saying the Trump administration "chose to proceed with an importation scheme that could endanger American lives, could worsen the opioid crisis and has been called unworkable by Canadian officials." However, former FDA commissioner Scott Gottlieb tweeted that the proposed rule had stringent safety conditions. "While it may sharply limit who can actually import Canadian drugs under this framework, it maintains critical FDA safeguards to protect consumers," he wrote. The SPDR S&P Biotech exchange-traded fund was down 0.61% in afternoon trading and is up 34% year-to-date. The S&P 500 has gained 27% year-to-date.
Here is a look at the 25 best and 25 worst ETFs from the past week. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby serving as potential starting points for those looking to take on either short or long positions. Likewise, traders can also use this list to spot potential trend reversal opportunities that may offer a generous risk/reward. As always, investors of all experience levels are advised to use stop-loss orders and practice disciplined profit-taking techniques. To get access to all ETFdb.com premium content, sign up for a free 14-day trial to ETFdb.com Pro.
Biotech has been a great performer since I suggested it as a contrarian play on Oct. 11. In that time, the SPDR S&P Biotech exchange-traded fund (XBI) climbed 22.8% through Thursday, and the iShares Nasdaq Biotechnology Index (IBB) advanced 19.8%, compared with a 6.4% gain for the S&P 500 (SPX) The seven stocks I singled out in that column have done well: They jumped 26.6%. “Washington is very focused on impeachment and trade talks,” says Jefferies biotech analyst Michael Yee.
A protection for drugmakers that has been cut from the proposed North American trade deal won’t matter for investors, analysts say. But they say the president’s willingness to roll over on the issue doesn’t bode well for the sector.
Bluebird bio is set to start earning money from drug sales next year, and SVB Leerink analyst Mani Foroohar is increasing his price target on the stock.
While all eyes are on the fate of the phase one trade deal between the United States and China, Healthcare sector can forget tension and soar higher in 2020 even if there is no deal.
After stumbling through much of 2019, biotechnology ETFs are finding their grooves in the fourth quarter. Since the start of the current quarter, the iShares Nasdaq Biotechnology ETF (IBB) is higher by more than 16% while the SPDR S&P Biotech ETF (XBI) is up 17.40%. Regardless of fund structure, data suggest investors have recently been returning to biotech funds.